projectstartups.com

Grey Wolf Therapeutics

Grey Wolf Therapeutics is a clinical-stage biotechnology company developing antigen modulation therapies to treat immune dysfunction in oncology and autoimmunity. Their lead candidate, GRWD5769, is an ERAP1 inhibitor in a Phase 1/2 clinical trial for solid tumors, with a second inhibitor, GRWD0715, targeting autoimmune diseases. The company's unique approach aims to modify antigen presentation to either stimulate or suppress immune responses.


Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $50M

Date: 23-May-2024

Investors: ICG's Life Sciences team, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises, British Patient Capital

Markets: Biotechnology, Immuno-oncology, Autoimmune Diseases, Therapeutics, Health Care

HQ: Abingdon, Oxfordshire, United Kingdom

Founded: 2017

Website: https://greywolftherapeutics.com/

LinkedIn: https://www.linkedin.com/company/greywolf-therapeutics

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/greywolf-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/235062-91

Download Funded Startups lists

Leave a Comment